Stifel on Mirum Pharmaceuticals (MIRM): 'We think the opportunity here remains under-appreciate'

October 12, 2026 9:30 AM

Stifel analyst James Condulis reiterated a Buy rating and $136.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst comments "Next ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found